Astellas Pharma (ALPMY) announced the Food and Drug Administration issued a Complete Response Letter regarding the supplemental new drug ...

JPMorgan says Astellas Pharma’s (ALPMY) (ALMPY) announcement that the FDA has issued a Complete Response Letter regarding for Izervay in ...

Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

"Astellas stands by the clinical profile of Izervay, the only FDA-approved GA treatment that consistently demonstrated ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

Astellas Pharma (JP:4503) has released an update. Astellas Pharma has received FDA approval for VYLOY, a novel treatment targeting CLDN18.2 for advanced gastric and gastroesophageal junction ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) saw a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 9,100 shares ...

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) reported first half profit of 73.51 billion yen, an increase of 105.3% from last year. Basic earnings per share was 41.06 yen, up 105.7%. Core ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Astellas Pharma has a 12-month low of $9.15 and a 12-month high of $13.14. The company has a market capitalization of $22.25 billion, a price-to-earnings ratio of 175.64 and a beta of 0.37.